Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease. (May 2016)

• Record Type: Journal Article
• Authors: Isaacson, Richard S.; Ferris, Steven; Velting, Drew M.; Meng, Xiangyi
• Is Part Of: American journal of Alzheimer's disease & other dementias. Volume 31:Number 3(2016)
• Page Start: 270
• Page End: 277
• Publication Date: 2016-05
• Subjects: cholinesterase inhibitor -- cognition -- randomized clinical trial -- rivastigmine patch -- severe Alzheimer's disease -- Severe Impairment Battery; Alzheimer's disease -- Periodicals; Dementia -- Periodicals; Alzheimer's disease -- Patients -- Care -- United States -- Periodicals; 616.83
• DOI: 10.1177/1533317515603687
• Languages: English
• ISSNs: 1533-3175

Abstract

Severe Impairment Battery (SIB) data from the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study suggest that patients with severe Alzheimer's disease (AD) benefit from treatment with 13.3 versus 4.6 mg/24 h rivastigmine patch. The objective of this retrospective analysis was to further examine the cognitive efficacy of 13.3 versus 4.6 mg/24 h rivastigmine patch on individual SIB items, and SIB domains derived using factor analysis of these items. Change from baseline at Week 24 on 9 new factor-defined domains and individual items was calculated and compared using effect sizes (Cohen's d). Numerically less decline was observed with 13.3 versus 4.6 mg/24 h patch on all domains and the majority of individual items. Largest least squares mean treatment differences were observed on "visuospatial reasoning, " "object naming, " "recognition, " "design copying, " "social agency, " "ideational praxis, " and "comprehension" domains. These findings suggest 13.3 mg/24 h rivastigmine patch demonstrates broad cognitive efficacy across a range of SIB items and domains in patients with severe AD.